PubMed Health⌕ Search

Biomedical subjects

T Mukojima

Publications and source records attributed to T Mukojima.

At least 19 recordsLinked to original sources
PubMed1991

[A case of recurrent hepatocellular carcinoma after hepatic resection surviving over five years by hepatic arterial infusion of lipiodol-anticancer drug suspension].

A 63-year-old male with four intrahepatic recurrences of surgically resected hepatocellular carcinoma was admitted to our hospital in June 1985. He underwent lateral segmentectomy of the liver in November 1983. Pathologic finding of Edmondson II with liver cirrhosis had been confirmed by the operative specimen. Sizes of four recurrent tumors were assessed by CT as 3.5 x 2.2 cm, 2.6 x 2.2 cm, 2.2 x 2.2 cm and 2.2 x 2.2 cm, respectively. During five years until July 1990, the patient was treated with hepatic arterial infusion of Lipiodol-anticancer drug suspension eight times (total 5-FU 900 mg, ADM 77 mg, MMC 73 mg, and Lipiodol 36 ml) and hepatic arterial chemoembolization of MMC microcapsules one time. In addition, two hepatic arterial infusions of CDDP (total 70 mg) were given and 5-FU (total 10 g) was administered intravenously. Partial response (PR) was obtained for 19 months. Hepatic arterial infusion of Lipiodol-anticancer drug suspension was given only once every 6 months, and he maintained a good quality of life for over four and half years. The man died in July 1990. In general, multiple intrahepatic recurrence of surgical resected hepatocellular carcinoma has a poor prognosis. Therefore it was considered that hepatic arterial infusion of this drug brought about the relatively long survival of more than five years.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1989

[Efficacy of UFT in advanced gastric carcinoma under comparative study of MMC + UFT and MMC + tegafur therapies].

Antitumor effect of MMC + UFT(A) and MMC + tegafur(B) therapies for advanced gastric carcinoma was compared from February 1985 to March 1988. UFT and tegafur were orally given at dose of 400 mg/m2 daily, and MMC was intravenously administered at dose of 6-8 mg/m2 every two weeks. The following results were obtained. 1. Twenty-nine cases entered in this study were divided into A or B therapies at random. All cases entered were eligible. Fourteen of 29 cases were randomized into A therapy and 15 cases into B therapy. One case treated with B was evaluated as incomplete. 2. There were no differences in the characteristics of patients between A and B therapies. 3. Among 29 eligible cases, a partial response was obtained in 3 out of 14 cases (21.4%) treated with A and in 3 out of 15 cases (20.0%) treated with B. Among 28 cases evaluated completely, a partial response was obtained in 3 out of 14 cases (21.4%) treated with each A and B. 4. Response rate with every ps or for every lesion did not differ between A and B therapies. 5. Median survival day treated with A and B therapies was 223 and 181 days, respectively. The survival curve did not differ significantly between the two therapies. 6. The frequency of adverse reactions within eight weeks after beginning the therapy was 64.2 and 73.3% with A and B therapies, respectively. From the results mentioned, it was concluded that the antitumor effect of UFT was not superior to that of tegafur for advanced gastric carcinoma.

Adult↗
PubMed1984

Reproducibility of the MS-2 system for identification of members of the family Enterobacteriaceae: a collaborative study with blindly assigned reference stains.

The reproducibility of identification and biochemical reactions for five different reference organisms of Enterobacteriaceae; Proteus vulgaris, Klebsiella pneumoniae, Escherichia coli, Serratia marcescens, and Enterobacter cloacae, were evaluated using the updated MS-2 system software (Abbott Laboratories, Diagnostic Division, Irving, Tex.) in a collaborative study involving 11 laboratories. When a total of 220 randomly coded test organisms were blindly examined, the MS-2 system correctly identified 92.7 and 86.8% for over 80 and 90% probability identification, respectively. Four organisms, P. vulgaris, K. pneumoniae, E. coli, and S. marcescens, were correctly identified in all laboratories with high probability, but 9 of 44 tests of Enterobacter cloacae resulted in misidentifications or low-likelihood (less than 80%) identifications. Accuracy was directly related to level of experience and familiarity with the MS-2 system in the individual laboratories. Biochemical reactions varied among the identification trials, especially in the identification of S. marcescens and Enterobacter cloacae. Among a total of 44 subcultures for each organism, 10 different biochemical patterns for P. vulgaris, 6 for K. pneumoniae, 9 for E. coli, 15 for S. marcescens, and 14 for Enterobacter cloacae were obtained. The results indicate that the MS-2 system performs with high accuracy and reproducibility in identifying Enterobacteriaceae, except for Enterobacter cloacae.

Bacteriological Techniques↗
PubMed1983

Distribution of alpha-fetoprotein and immunoreactive carcinoembryonic antigen in human hepatocellular carcinoma and hepatoblastoma.

The distribution of alpha-fetoprotein (AFP) and immunoreactive carcinoembryonic antigen (CEA) in 62 hepatocellular carcinomas (HCC) and five hepatoblastomas (HBL) all surgically removed was studied by an immunohistochemical method, and the results were compared with the levels of the antigens in the patients' serum. AFP was present as coarse granules in the cytoplasm of immature tumor cells. AFP-positive tumor cells were detected in 34/43 cases (79.1%) with serum AFP levels higher than 400 ng/ml and in 1/24 (4.2%) of the remaining cases. They were present in 8/32 (25%) cases of relatively well-differentiated HCC (Edmondson's grade I or II), 22/32 (68.8%) of relatively poorly differentiated HCC (Edmondson's grade III or IV), and 5/5 of HBL. An antigen immunoreactive with a conventional rabbit anti-CEA immunoglobulin (DAKO) but not with a murine monoclonal anti-CEA antibody (Hybritech) was present on the surface of bile canaliculi of both non-neoplastic and neoplastic hepatocytes. This CEA cross-reactive differentiation antigen was more often found in relatively well-differentiated tumors, and the presence of this antigen in tumors did not correlate with patients' serum CEA levels. In conclusion, CEA of an oncofetal nature was not produced by either HCC or HBL.

Carcinoembryonic Antigen↗
PubMed1981

Production of alpha-fetoprotein, normal serum proteins, and human chorionic gonadotropin in stomach cancer: histologic and immunohistochemical analyses of 35 cases.

By immunoperoxidase histochemical staining of formalin-fixed paraffin-embedded sections, the production of alpha-fetoprotein(AFP), albumin(ALB), transferrin(TF), alpha-1-antitrypsin(AAT), and human chorionic gonadotropin(HCG) was examined in 35 operatively resected stomach cancers with elevated serum AFP levels (higher than 20 ng/ml as determined by radioimmunoassay). Cells positive for AFP were found in 19 cases (54%). In 29 cases (83%), some tumor cells contained normal serum proteins (ALB, TF, or AAT). All 19 tumors with AFP-positive cells also stained positively for two or three kinds of normal serum proteins. In some cases, AFP and normal serum proteins were localized in the same cells. There were two cases in which metastatic tumors produced AFP, whereas the primary sites did not. In nine cases (26%), HCG was present in tumor cells and HCG- and AFP-positive cells were coexistent in six tumors. Histologic examination of AFP-producing stomach tumors revealed medullary or papillotubular arrangements with marked nuclear atypia and eosinophilic granular or clear cytoplasms containing no glycogen or mucin. Some tumors with medullary patterns resembled liver cell carcinomas. Concordant phenotypic expression of AFP and normal serum protein production appears to be a general feature of AFP-producing tumors such as liver cell carcinoma, yolk sac tumor, and stomach cancer.

Blood Proteins↗
PubMed1978

Chemotherapy of human choriocarcinoma transplanted to nude mice.

Two human choriocarcinomas serially transplanted to athymic nude mice (BALB/c, nu/nu) were treated with intraperitoneal injections of methotrexate (MTX), actinomycin D (ACTD), and vinblastine (VLB) with doses per injection slightly smaller than LD10 in mice. Both ACTD and VLB significantly suppressed the growth of one tumor strain (SCH) but MTX did not. The growth of another tumor strain (CC-1) was not inhibited by either ACTD or VLB. In strain SCH, plasma HCG of tumor-bearing animals increased approximately in parallel with the growth of tumors in control and MTX-, ACTD-, and VLB-treated groups but the suppression of the hormone release was more marked in the ACTD-treated group. The results indicate that these two transplantable human tumors are useful models for the study of choriocarcinoma, particularly for therapeutic experiments.

Adult↗